Dermatite atopique: physiopathologie et nouveaux traitements

Dermatite atopique: physiopathologie et nouveaux traitements

Ces dernières années, de nouveaux traitements efficaces ont été développés et permettent enfin de soulager nos patients atteints de dermatite atopique modérée à sévère. Comprendre la physiopathologie de cette dermatose inflammatoire chronique et invalidante nous permet de comprendre le mode d’action des nouveaux traitements, déjà approuvés ou encore à l’étude.

The relationship of improvements in itch and sleep disturbance with quality of life in patients with Atopic Dermatitis treated with baricitinib

The relationship of improvements in itch and sleep disturbance with quality of life in patients with Atopic Dermatitis treated with baricitinib

Itch is the lead symptom of atopic dermatitis (AD), impacting sleep and quality of life (QoL), and is a key component of scales assessing patient reported AD severity. Here, we report the effect of baricitinib (BARI), an oral, selective Janus kinase (JAK) 1 and 2 inhibitor, on frequency and severity of itch and sleep disturbance, and the correlation between improvements in these parameters with QoL over 16 weeks in patients from BREEZE-AD4.

Futurs évènements